Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236713 | 1.00 | CHRM2 (0.52) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL9444152 | 0.98 | ALDH1A1 (0.53) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL8935492 | 0.89 | CHRM2 (0.46) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Acetic Acid SCHEMBL11614488 | 0.83 | ALDH1A1 (0.51) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL28273440 | 0.81 | ALDH1A1 (0.49) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL5171234 | 0.79 | ALDH1A1 (0.51) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL2495325 | 0.79 | ALDH1A1 (0.51) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL1617171 | 0.79 | ALDH1A1 (0.51) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL13517084 | 0.77 | ALDH1A1 (0.46) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL5167294 | 0.77 | ALDH1A1 (0.46) | CHRM2CHRM1MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140288118-A1 | N-BIARYLAMIDES | BAYER INTELLECTUAL PROPERTY GMBH | 2014-09-25 | — | — | US | disclosed |
| US-20120157490-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-8030329-B2 | N-biarylamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | CHRNA7, CHRNA3, CHRNA5 | CHRM2 45/4885CHRM1 42/4885MEN1 4500/4885 |
| US-20140288118-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | CHRM2 479/4885CHRM1 919/4885MEN1 2378/4885 |
| US-20120157490-A1 | N-BIARYLAMIDES | GRIN2A, BCHE, ACHE | CHRM2 127/4885CHRM1 171/4885MEN1 3205/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | CHRM2 479/4885CHRM1 919/4885MEN1 2378/4885 |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | CHRNA7, CHRNA3, CHRNA2 | CHRM2 66/4885CHRM1 67/4885MEN1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.